ROCKET PHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $256.51M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | After market close | – | $1.08 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | – | $-0.42 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | After market close | – | $-0.38 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | – | $-0.45 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | – | $-0.62 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | – | $-0.56 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | After market close | – | $-0.62 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | – | $-0.71 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 5, 2024 | After market close | – | $-0.74 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 6, 2024 | After market close | – | $-0.66 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 26, 2024 | After market close | – | $-0.64 | – |
Press releases
Announcements Rocket Pharmaceuticals filed with the SEC
Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
RP-A501 Danon Disease Program Update © 2026 Rocket Pharmaceuticals Rocket
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete
Regulation FD disclosure · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients
Regulation FD disclosure · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Announces Closing of Sale of
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Announces FDA Approval of
Regulation FD disclosure · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal
Other events · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and
Other events · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Provides Update on
Regulation FD disclosure · EX-99.1 to Form 8-K
NVESTOR DE I CK INVESTOR DECK INVESTOR DECK Preliminary Data from Phase 1 Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Provides Regulatory Update on
Other events · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
Results of operations · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
Results of operations · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI TM (marnetegragene autotemcel) for the Treatment of Severe
Other events · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with
Other events · EX-99.1 to Form 8-K
S E E K I N G G E N E T H E R A P Y C U R E S Rocket Pharmaceuticals Danon
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design in RP-A501 in Danon Disease
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
Results of operations · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease
Other events · EX-99.1 to Form 8-K
INVESTOR DECK INVESTOR DECK INVESTOR DECK 41st Annual J.P. Morgan Healthcare
Other events · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM
Other events · EX-99.2 to Form 8-K
Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease
Other events · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Completes Acquisition of Renovacor
Acquisition or disposition completed · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
Results of operations · EX-99.1 to Form 8-K
Update from Phase 1 Trial of RP-A501 Gene Therapy Treatment for Danon
Other events · EX-99.1 to Form 8-K
THIS VOTING AGREEMENT (this “ Agreement ”) is made and entered into as of September __, 2022, by and between Renovacor, Inc., a Delaware corporation (the “ Company ”) and the undersigned
Material agreement · Other events · EX-99.1 to Form 8-K